SCHEMBL23478138

SCHEMBL23478138

Brc1cncc2c1cnn2C1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
POLB P06746 2/20 0.42
LMNA P02545 1/20 0.42
RXRA P19793 1/20 0.41
RXRB P28702 1/20 0.41
RXRG P48443 1/20 0.41
CYP4F2 P78329 3/20 0.39
CYP4A11 Q02928 3/20 0.39
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RET P07949 1/20 0.33
ATR Q13535 8/20 0.33
PDE9A O76083 1/20 0.33
CYP2C19 P33261 1/20 0.32
MEN1 O00255 1/20 0.31
ACVRL1 P37023 1/20 0.31
ACVR1 Q04771 1/20 0.31
PDE1A P54750 1/20 0.31
PDE1B Q01064 1/20 0.31
PDE1C Q14123 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30891904 1.00 ALDH1A1 (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL29416187 0.82 RXRA (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL156398 0.82 RXRA (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL25795329 0.81 RXRA (0.46) ALDH1A1POLBLMNARXRARXRB
SCHEMBL15209141 0.81 CYP4F2 (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL22499396 0.81 ALDH1A1 (0.40) ALDH1A1POLBLMNARXRARXRB
SCHEMBL17731741 0.81 RXRA (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL31128164 0.81 CYP4F2 (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL31128154 0.81 CYP4F2 (0.42) ALDH1A1POLBLMNARXRARXRB
SCHEMBL14723573 0.81 CYP4F2 (0.42) ALDH1A1POLBLMNARXRARXRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2025-01-02 US disclosed
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors EPICS THERAPEUTICS (BE) 2024-09-17 US disclosed
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS EPICS THERAPEUTICS (BE) 2024-08-15 US disclosed
WO-2024042316-A1 PYRIDO-PYRAZOLES AS INHIBITORS OF DDR'S FOR THE TREATMENT OF FIBROTIC DISORDERS AND CANCER REDX PHARMA PLC. (GB) 2024-02-29 WO disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2021113436-A1 INHIBITORS OF HIF-2ALPHA ARCUS BIOSCIENCES, INC. (US) 2021-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270716-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 ALDH1A1 205/4885POLB 847/4885LMNA 3137/4885
US-20250002475-A1 PIPERIDINE DERIVATIVES AS METTL3 INHIBITORS METTL3, METTL16, DIMT1 ALDH1A1 205/4885POLB 847/4885LMNA 3137/4885
US-12091400-B2 Piperidine derivatives as METTL3 inhibitors METTL3, METTL16, DIMT1 ALDH1A1 205/4885POLB 847/4885LMNA 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.